SAN DIEGO, Jan. 19, 2011 /PRNewswire/ --Santarus, Inc. (Nasdaq: SNTS)announces that a live audio webcast and accompanying slide presentation will be provided for its Analyst Day and Investor Briefing.
Details of the event are as follows:
What: | Santarus Analyst Day and Investor Briefing | |
When: | Today, Wednesday, January 19, 2011 at 4:15 p.m. Eastern time | |
Where: | www.santarus.com (under the Investor Relations link) | |
AGENDA
- Strategic Overview and 2011 Financial Outlook
Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc.
- CYCLOSET® - Clinical/Medical Background
Dr. J. Michael Gaziano, Chief, Division of Aging, Brigham & Womens Hospital,
Professor of Medicine, Harvard Medical School
- ULTESA (Budesonide MMX®) Overview and Top-line Phase III Clinical Study Results
Dr. Simon P.L. Travis, Consultant Gastroenterologist,
Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK
- Ulcerative Colitis Treatment Perspective
Dr. William J. Sandborn, Professor of Clinical Medicine and Chief of the Division of Gastroenterology,
University of California, San Diego
- RHUCIN® and Hereditary Angioedema (HAE)
Dr. Bruce L. Zuraw, Professor of Medicine and Chief, Allergy and Immunology, University of California, San Diego,
Research Scientist, San Diego VA Healthcare
- SAN-300 (anti-VLA-1 antibody)
Dr. Mark C. Totoritis, Senior Vice President, Biologics, Santarus, Inc.
- Wrap-up/Question & Answer Session
Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc.
How: | Live over the Internet Simply log on to the Investor Relations section of the company’s website at www.santarus.com | |
Contact: | |
Lippert/Heilshorn & Associates | |
Narine Darbinyan | |
310-691-7100 | |
About Santarus
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company’s current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Santarus also has a diverse development pipeline with three late-stage product candidates in Phase III clinical programs: ULTESA (budesonide MMX®) for induction of remission of active ulcerative colitis, RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX® for treatment of travelers’ diarrhea. In addition, Santarus plans to initiate a Phase I clinical study in the first half of 2011 with SAN-300, its anti-VLA-1 antibody, which the company expects to investigate for the treatment of rheumatoid arthritis.
Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus’ business, including, without limitation: difficulties or delays in development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus’ products; and other risks detailed in Santarus’ prior press releases as well as in public periodic filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Santarus® and ULTESA are trademarks of Santarus, Inc. GLUMETZA® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc. CYCLOSET® is a trademark of VeroScience LLC. MMX® is a trademark of Cosmo Technologies Limited. RHUCIN® is a trademark of Pharming Group NV.
SOURCE Santarus, Inc.
